Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Summary

This phase II trial studies how well pembrolizumab works in treating patients with uveal melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.

Timeline

Start

2015-05

Primary completion

2017-05

Completion

2019-08-27

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Publications

• Johnson DB, Bao R, Ancell KK, Daniels AB, Wallace D, Sosman JA, Luke JJ. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. J Natl Compr Canc Netw. 2019 Feb;17(2):114-117. doi: 10.6004/jnccn.2018.7070.

Drugs

Indications